Clairvoyant Therapeutics, a Canadian drug developer, has initiated the first of 15 planned sites for the Phase 2 CLARITY clinical study investigating the use of magic mushroom molecule psilocybin to treat alcohol use disorder (AUD).
The randomized, placebo-controlled study will evaluate the safety and efficacy of 25 mg of synthetic psilocybin with Motivational Enhancement Therapy (MET), a counseling method designed to elicit an internally motivated behavior change regarding substance abuse.
The CLARITY trial has won regulatory approval. Clairvoyant is currently working on obtaining regulatory approval to expand the trial to a number of EU countries.
Edmonton, Alberta-based Clairvoyant Therapeutics aims to win regulatory approval for psilocybin therapy in the EU, UK and Canada by 2026.
The CLARITY trial provides “a great opportunity to advance the science on psilocybin than has historically been done,” said Greg Engel, Clairvoyant Thera…